Canada Pension Plan Investment Board Boosts Stake in United Therapeutics Co. (NASDAQ:UTHR)

Posted by Defense World Staff on Feb 27th, 2023

Canada Pension Plan Investment Board raised its position in United Therapeutics Co. (NASDAQ:UTHR – Get Rating) by 258.6% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 10,400 shares of the biotechnology company’s stock after buying an additional 7,500 shares during the period. Canada Pension Plan Investment Board’s holdings in United Therapeutics were worth $2,178,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. DekaBank Deutsche Girozentrale increased its stake in United Therapeutics by 0.4% in the 3rd quarter. DekaBank Deutsche Girozentrale now owns 26,081 shares of the biotechnology company’s stock valued at $5,362,000 after buying an additional 92 shares during the last quarter. Rockefeller Capital Management L.P. grew its position in shares of United Therapeutics by 141.3% during the 3rd quarter. Rockefeller Capital Management L.P. now owns 794 shares of the biotechnology company’s stock valued at $166,000 after acquiring an additional 465 shares during the period. Twin Tree Management LP grew its position in shares of United Therapeutics by 273.0% during the 3rd quarter. Twin Tree Management LP now owns 4,457 shares of the biotechnology company’s stock valued at $933,000 after acquiring an additional 3,262 shares during the period. Oppenheimer & Co. Inc. grew its position in shares of United Therapeutics by 41.3% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 9,287 shares of the biotechnology company’s stock valued at $1,945,000 after acquiring an additional 2,713 shares during the period. Finally, Ronald Blue Trust Inc. bought a new position in shares of United Therapeutics during the 2nd quarter valued at approximately $28,000. Hedge funds and other institutional investors own 95.63% of the company’s stock.

United Therapeutics Stock Up 0.6 %

Shares of NASDAQ:UTHR opened at $249.76 on Monday. The firm has a fifty day moving average price of $262.92 and a two-hundred day moving average price of $245.76. The company has a debt-to-equity ratio of 0.17, a current ratio of 9.85 and a quick ratio of 9.55. United Therapeutics Co. has a one year low of $158.38 and a one year high of $283.09. The company has a market cap of $11.56 billion, a price-to-earnings ratio of 16.63, a PEG ratio of 1.80 and a beta of 0.63.

United Therapeutics (NASDAQ:UTHR – Get Rating) last announced its quarterly earnings results on Wednesday, February 22nd. The biotechnology company reported $2.67 EPS for the quarter, missing the consensus estimate of $4.12 by ($1.45). United Therapeutics had a net margin of 37.56% and a return on equity of 16.30%. The firm had revenue of $491.50 million during the quarter, compared to the consensus estimate of $519.20 million. During the same period in the previous year, the business earned $2.35 earnings per share. The firm’s revenue for the quarter was up 18.4% on a year-over-year basis. Analysts anticipate that United Therapeutics Co. will post 18.5 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on UTHR. Morgan Stanley reduced their target price on shares of United Therapeutics from $330.00 to $320.00 and set an “overweight” rating for the company in a research report on Thursday. JPMorgan Chase & Co. increased their target price on shares of United Therapeutics from $265.00 to $280.00 and gave the company an “overweight” rating in a research report on Thursday. Oppenheimer increased their target price on shares of United Therapeutics from $325.00 to $375.00 and gave the company an “outperform” rating in a research report on Thursday, November 3rd. The Goldman Sachs Group started coverage on shares of United Therapeutics in a report on Monday, December 5th. They issued a “sell” rating and a $230.00 price objective for the company. Finally, LADENBURG THALM/SH SH cut their price objective on shares of United Therapeutics from $295.00 to $285.00 in a report on Thursday. Two research analysts have rated the stock with a sell rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $291.55.

Insider Buying and Selling at United Therapeutics

In other news, CEO Martine A. Rothblatt sold 8,000 shares of the firm’s stock in a transaction on Wednesday, November 30th. The shares were sold at an average price of $277.53, for a total transaction of $2,220,240.00. Following the sale, the chief executive officer now owns 130 shares in the company, valued at approximately $36,078.90. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other news, CEO Martine A. Rothblatt sold 8,000 shares of the firm’s stock in a transaction on Wednesday, November 30th. The shares were sold at an average price of $277.53, for a total transaction of $2,220,240.00. Following the sale, the chief executive officer now owns 130 shares in the company, valued at approximately $36,078.90. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Paul A. Mahon sold 12,000 shares of the firm’s stock in a transaction on Thursday, December 15th. The shares were sold at an average price of $196.31, for a total transaction of $2,355,720.00. Following the sale, the executive vice president now owns 36,397 shares in the company, valued at approximately $7,145,095.07. The disclosure for this sale can be found here. Insiders sold a total of 199,420 shares of company stock valued at $52,271,649 in the last three months. Company insiders own 12.40% of the company’s stock.

About United Therapeutics

(Get Rating)

United Therapeutics Corp. operates as a biotechnology company engaged in the development and commercialization of products for patients with chronic and life-threatening diseases. The firm markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. It is involved in the development of novel pharmaceutical therapies and technologies that expand the availability of transplantable organs.